http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Precise measurement of hadronic <i>τ</i>-decays with an <i>η</i> meson
Inami, K.,Ohshima, T.,Kaji, H.,Adachi, I.,Aihara, H.,Arinstein, K.,Aulchenko, V.,Aushev, T.,Bedny, I.,Bhardwaj, V.,Bondar, A.,Brač,ko, M.,Browder, T.E.,Chang, M.-C.,Chao, Y.,Chistov, R.,Cho, I.-S Elsevier 2009 Physics letters: B Vol.672 No.3
<P><B>Abstract</B></P><P>We have studied hadronic <I>τ</I> decay modes involving an <I>η</I> meson using 490 fb<SUP>−1</SUP> of data collected with the Belle detector at the KEKB asymmetric-energy <SUP>e+</SUP><SUP>e−</SUP> collider. The following branching fractions have been measured: B(<SUP>τ−</SUP>→<SUP>K−</SUP>η<SUB>ντ</SUB>)=(1.58±0.05±0.09)×<SUP>10−4</SUP>, B(<SUP>τ−</SUP>→<SUP>K−</SUP><SUP>π0</SUP>η<SUB>ντ</SUB>)=(4.6±1.1±0.4)×<SUP>10−5</SUP>, B(<SUP>τ−</SUP>→<SUP>π−</SUP><SUP>π0</SUP>η<SUB>ντ</SUB>)=(1.35±0.03±0.07)×<SUP>10−3</SUP>, B(<SUP>τ−</SUP>→<SUP>π−</SUP>KS0η<SUB>ντ</SUB>)=(4.4±0.7±0.2)×<SUP>10−5</SUP>, and B(<SUP>τ−</SUP>→<SUP>K∗−</SUP>η<SUB>ντ</SUB>)=(1.34±0.12±0.09)×<SUP>10−4</SUP>. These results are substantially more precise than previous measurements. The new measurements are compared with theoretical calculations based on the CVC hypothesis or the chiral perturbation theory. We also set upper limits on branching fractions for <I>τ</I> decays into <SUP>K−</SUP>KS0η<SUB>ντ</SUB>, <SUP>π−</SUP>KS0<SUP>π0</SUP>η<SUB>ντ</SUB>, <SUP>K−</SUP>ηη<SUB>ντ</SUB>, <SUP>π−</SUP>ηη<SUB>ντ</SUB> and non-resonant <SUP>K−</SUP><SUP>π0</SUP>η<SUB>ντ</SUB> final states.</P>
Shinya Sato,Kei Moriya,Masanori Furukawa,Soichiro Saikawa,Tadashi Namisaki,Mitsuteru Kitade,Hideto Kawaratani,Kosuke Kaji,Hiroaki Takaya,Naotaka Shimozato,Yasuhiko Sawada,Kenichiro Seki,Koh Kitagawa,T 대한간학회 2019 Clinical and Molecular Hepatology(대한간학회지) Vol.25 No.1
Background/Aims: L-carnitine not only alleviates hyperammonemia and reduces muscle cramps in patients with liver cirrhosis, but also improves anemia in patients with chronic hepatitis and renal dysfunction. This study prospectively evaluated the preventative efficacy of L-carnitine supplementation against hemolytic anemia during antiviral treatment using ribavirin in patients with hepatitis C virus (HCV)-related chronic liver disease. Methods: A total of 41 patients with chronic hepatitis were consecutively enrolled in this study. Group A (n=22) received sofosbuvir plus ribavirin for 3 months, whereas group B (n=19) was treated with sofosbuvir, ribavirin, and L-carnitine. Hemoglobin concentration changes, the effects of antiviral treatment, and the health status of patients were analyzed using short form-8 questionnaires. Results: A significantly smaller decrease in hemoglobin concentration was observed in group B compared to group A at every time point. Moreover, the prescribed dose intensity of ribavirin in group B was higher than that of group A, resulting in a higher ratio of sustained virological response (SVR) 24 in group B compared with group A. The physical function of patients in group B was also significantly improved compared to group A at the end of antiviral treatment. Conclusions: L-carnitine supplementation alleviates ribavirin-induced hemolytic anemia in patients with HCV and helps relieve the physical burden of treatment with ribavirin-containing regimens. These advantages significantly increase the likelihood of achieving SVR.
Search for proton decay viap→νK+using260 kiloton·yeardata of Super-Kamiokande
Abe, K.,Hayato, Y.,Iyogi, K.,Kameda, J.,Miura, M.,Moriyama, S.,Nakahata, M.,Nakayama, S.,Wendell, R. A.,Sekiya, H.,Shiozawa, M.,Suzuki, Y.,Takeda, A.,Takenaga, Y.,Ueno, K.,Yokozawa, T.,Kaji, H.,Kajita American Physical Society 2014 PHYSICAL REVIEW D - Vol.90 No.7